PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...
In this inaugural episode of the Ophthalmology Times ® “Beyond The Walls” podcast, host Deborah Ristvedt, DO, of Vance ...
4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...
Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board, bringing expertise from Jeito Capital, BioMedPartners, and Roche.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback